Skip to main content
An official website of the United States government

Funded Grants

PI Name Sort descending PI Organization Title Grant Number Initiative Program Official
Shiozawa, Yusuke

Wake Forest University Health Sciences
United States

Contribution of cutaneous neuro-immune interactions to chemotherapy-induced peripheral neuropathy 1R21CA297068-01 Rachel Altshuler, Ph.D.
Shirwan, Haval

University Of Missouri-Columbia
United States

Developing a novel agonist of CD137 for cancer immunoprevention 1UG3CA290305-01 Altaf Mohammed, Ph.D.
Shu, Xiao-Ou

Vanderbilt University Medical Center
United States

Use of Circulating MicroRNAs for Early Detection and Risk Assessment for Pancreatic Cancer 5R01CA227133-05 Matthew Young, Ph.D.
Shuck, Sarah C.

Beckman Research Institute/City Of Hope
United States

Identification of metabolic adducts associated with prostate cancer progression in African American men Supplement 3R21CA282612-01S1 Guillermo Marquez, Ph.D.
Shureiqi, Imad

University Of Michigan At Ann Arbor
United States

ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism 5R01CA266223-04 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Siddique, Shahzad

Commonspirit Health Research Institute
United States

CIRI Oncology Research Alliance 5UG1CA189809-11 Vanessa A. White, M.P.H.
Sidransky, David

Johns Hopkins University
United States

Racial differences in Immunogenetic Tumorigenesis of Head and Neck Squamous Cell Carcinoma 5R01CA265975-03 Wendy Wang, Ph.D., M.Sc.
Sieren, Jessica C

University Of Iowa
United States

Lung cancer screening efficacy enhanced through radiomic and epigenetic biomarkers 5R01CA267820-03
Sigel, Keith Magnus

Icahn School Of Medicine At Mount Sinai
United States

The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors 5R01CA256660-04 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Simeone, Diane M

University Of California, San Diego
United States

Biomarker Validation in Pancreatic Cystic Neoplasms 7U01CA282272-02 PAR-21-334 (U01 Clinical Trial Optional) Matthew Young, Ph.D.